

SCHIZOPHRENIA REFERENCES

1. Akerfeldt, S.: Blood tests in mental disease. Papers and Discussions presented at the Annual Scientific Conference of the Brain Research Foundation, Chicago, 1957.
2. Abood, L. G., Gibbs, F. A. and Gibbs, E.: Comparative study of blood Ceruloplasmin in schizophrenia and other disorders. *Arch. Nerv. Psychiat.* 77:643-45, 1957.
3. Angel, C, Leach, B. E., Martens, S., Cohen, M. and Heath, R. G.: Serum oxidation tests in schizophrenic and normal subjects. *Arch. Nerv. Psychiat.* 78:500-504, 1957.
4. McDonald, R. K.: Problems in biologic research in schizophrenia. *J. Chron. Dis.* 366-371, 1958.
5. Sebrell, W. H. and Harris, R. S.: *The Vitamins Vol. I*, 2nd Ed. New York, Academic Press, 1967.
6. VanderKamp, H.: A biochemical abnormality in schizophrenia involving ascorbic acid. *Int. J. Neuropsychiat.* 2:204-206, 1966.
7. Cowen, M. A.: Schizophrenic hallucinations and the transephalic D.C. potential. *Arch. of Gen. Psychiat.* 18:114-116, 1968.
8. Cowen, M. A. and Cassell, W.: Some aspects of the baseline transephalic D.C. potential in psychiatric patients. *J. Psychiat. Res.* 6 (In press), 1968.
9. Cowen, M. A.: Manuscript in Preparation.
10. Maricq, H. R.: A study of subpapillary plexus in the nail fold in mental defectives. *J. Nerv. Ment. Dis.* 139:287-293, 1964.
11. Maricq, H. R.: Capillary morphology and the course of illness in schizophrenic patients. *J. Nerv. Ment. Dis.* 142:63-71, 1966.
12. Norris, A. S.: Prognosis and capillary morphology. *J. Nerv. Ment. Dis.* 142:369-375, 1966.
13. Weckowicz, T. E. and Hall, R.: Skin histamine test in schizophrenia. *J. Nerv. Ment. Dis.* 125:452-458, 1957.
14. Weckowicz, T. E. and Hall, R.: Skin histamine reaction in schizophrenic and non-schizophrenic mental patients. *J. Nerv. Ment. Dis.* 126:415-420, 1958.

AWARD OFFERED

The Dixie Annette Award of \$10,000 (minimum) is being offered for the development of a cure for schizophrenia. The award is administered by the American Schizophrenia Foundation.

Description of patients. The American Psychiatric Association's definition and criteria for the diagnosis of schizophrenia shall apply. Supporting psychometric or biochemical evidence, or both, may be required. The diagnosis must be acceptable to the Foundation Board of Trustees.

General requirements. The cure (complete absence of schizophrenic symptoms) must be accomplished within one year of initiation of treatment and must be maintained for five years without remission from the date on which classification was assigned. Any and all treatment methods may be applied and, if necessary, be continued throughout the required five year cure period.

The treatment method must be effective in 90 percent of a minimum sample of 50 consecutively selected schizophrenic patients.

All clinical data must be presented to the Foundation Trustees, along with authorization to examine the patients.

The sample and treatment procedure must be described in a manner that will permit replication by an investigator(s) whom the Foundation will appoint.

Trustees of the Foundation are not eligible for the award.